USE OF 1-ALPHA-HYDROXYVITAMIN D5 AND RELATED COMPOUNDS AS PROPHYLACTIC OR THERAPEUTIC AGENTS FOR SARS-COV-2 (COVID-19 VIRUS) AND RELATED INFECTIONS
Number of patents in Portfolio can not be more than 2000
United States of America
Stats
-
N/A
Issued Date -
Feb 24, 2022
app pub date -
Aug 17, 2021
filing date -
Aug 17, 2021
priority date (Note) -
Published
status (Latency Note)
Importance
Abstract
The use of 1-alpha-hydroxyvitamin D5 or related compounds as prophylactic or therapeutic agents for SARS-CoV-2 (Covid-19 virus) and related infections. The compounds may be administered orally, by inhalation, nasal spray, eye drops, or by injection. The compounds may be administered to persons who are unwilling, unable or adverse to be vaccinated. The compounds also may be administered to immunocompromised persons for whom vaccination may not provide adequate protection from infection.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully